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Abstract 
Background: The majority of people living with HIV/AIDS (PLWHA) reside in low- and middle-income 
countries. HIV-associated neuro-cognitive disorders (HAND) are among the most common neurological 
complications, especially in resource-limited countries. HAND occurs in all stages of HIV infection, but the risk 
increases with advanced infection. This study measures the magnitude of HAND and associated factors among 
HIV patients. 
Methods and Materials: A hospital-based cross-sectional study was employed among 581HIV-positive patients 
using a systematic random sampling technique to select participants. The International HIV Dementia Scale 
(IHDS) was used to assess cognitive impairment. The collected data were coded and entered into Epi-data 3.1 and 
analyzed using SPSS version 20.0. Bivariate and multivariate analysis was carried out and interpreted using odds 
ratio and 95% confidence interval at p-value < 0.05.  
Results: Five hundred and eighty-one HIV patients were involved in this study, making the response rate 99.49%. 
Of the total participants, 35.6% had HAND. Being illiterate (AOR: 5.16; 95% CI: 2.20-12.07), having a primary-
level education (AOR: 3.27; 95% CI: 1.46-7.29), having a CD4 count (cells/µl) ≤ 500 (AOR: 1.61; 95% CI: 1.11-
2.39) and the lifetime use of tobacco (AOR: 2.40; 95% CI: 1.44-4.01) were significantly associated with HAND. 
Conclusions: A high prevalence of HAND was observed. Being illiterate, a primary-level education, and a low 
CD4 count and tobacco use were significantly associated. [Ethiop. J. Health Dev. 2020; 34(1):22-29] 
Key words: HIV-associated neuro-cognitive disorder, International HIV Dementia Scale, Ethiopia 
 
Introduction  
Human immunodeficiency virus (HIV) is the causative 
agent of acquired immunodeficiency syndrome 
(AIDS), which is a multi-system disorder involving the 
central nervous system (CNS) (1). It causes a wide 
range of neuro-cognitive complications grouped under 
the acronym ‘HAND’ (HIV-associated neuro-cognitive 
disorders) (2). One of the most frequent complications 
is the disruption of neuro-cognitive function (3), which 
leads to vulnerability to the cognitive effects of other 
conditions (4). HIV-associated dementia (HAD) is the 
most severe manifestation of HIV-associated neuro-
cognitive disorder (HAND) (5). 
 
Several studies have estimated the prevalence of 
HAND to range from 20% to 50%, despite effective 
antiretroviral therapy (ART). The disorder has an effect 
on social and work interactions, reduces the patient’s 
adherence to ART, increases the risk of cognitive 
decline, and ultimately leads to deterioration in quality 
of life, according to a study conducted in Germany (6). 
It has long been recognized that the direct effects of 
HIV on the brain lead to neuro-cognitive impairment 
and, if left untreated, progress to HAD (7). 
 
More than 70% of the world’s HIV-positive population 
lives in sub-Saharan Africa. HIV-positive individuals 
throughout this region tend to have worse 
neuropsychological function (8). HAND may include 
neurological disorders of various severities. prevalence 
of HAND in HIV/AIDS patients in Western countries is 
10-24% (9).   
In a cross-sectional study conducted in Switzerland, 
there was a prevalence of HAND in 74% of patients 
with evidence of cognitive decline (10). Poor 
immunological status, reflected by lower nadir CD4 
cell count, has been associated with neuro-cognitive 
impairment before and after HAART (3). According to 
study conducted in Brazil, the prevalence of HAND 
among HIV/AIDS patients was 22.7% (11). Increasing 
age (OR: 1.104; 95% CI: 1.054-1.155, p<0.001), lower 
educational level (OR: 0.78; 95% CI: 0.69-0.89, 
p<0.001) and lower baseline CD4 count (OR: 0.15; 
95% CI: 0.03-0.74, p<0.001) were associated with 
HAND (10, 12). HAND, even in its mild form, is 
associated with lower medication adherence, a 
decreased ability to perform the most complex daily 
tasks, poor quality of life, and difficulty obtaining 
employment. The prevalence of HAND among 
HIV/AIDS patients as found to be around 33.3% 
according to study done in Ethiopia (13). 
 
According to studies done in northern Nigeria and 
multi-center study conducted by student at Pittsburgh 
University the prevalence of HAND among HIV/AIDS 
patients was 21.5% (95% CI = 17.6-25.4) and 34.45%, 
respectively. In these study cognitive impartment was 
significantly associated with low CD4 count, high viral 
load, low level of education, being confined to bed, and 
poor adherence to ART in the past (9, 14) . According 
to study done in Yaoundé, Cameroon, it was found that 
22.2% of study participants had HAND (15). HAND 
increases morbidity and health burden and significantly 
decreased the quality of life (8). Study done in different 
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area shows lower level of education and decreased 
CD4 count was significantly associated with HAND 
among HIV/AIDS patients (16) (1) (17, 18).  
 
Study done in Malawi, the prevalence of HAND 
was ranges from 19% to 52% in patients on 
combination anti-retroviral therapy in high 
resource settings, and from 14% to 64% in low 
resource settings (19). In a study of HIV-positive 
outpatients in Uganda, nearly one third met the criteria 
for HAD, with advanced age and low CD4 (18). In a 
South African study, 25% of HIV-positive individuals 
on combination ART met the criteria for HAD, and an 
additional 42% met the criteria for mild neuro-
cognitive disorder (MND) (20). 
 
In Ethiopia, different studies of HIV-positive patients 
show that 35.7% in south west Ethiopia (Jimma), 
24.8% in north west Ethiopia (Debre Markos), 36.4% 
in South Wollo and 33.3% in northern Ethiopia 
(Mekelle) had HAND. Age, level of education, 
medication adherence and CD4 count were statistically 
significant (13, 21-23). 
 
Starting highly active anti-retroviral therapy 
(HAART) early may decrease the progression of HIV and 
increase CD4 count. But still there is high level of HAND. 
So, the aim of this study was to determine the 
prevalence and associated factors of HAND among 
PLWHIV. Showing the prevalence of HAND and the 
factors associated with it may prove useful to 
stakeholders and policy-makers working in neuro-
psychiatry. 
 
Methods and Materials 
Study design and area: This hospital-based cross-
sectional study design was employed among HIV-
positive patients visiting the ART clinics of four 
federal hospitals in Addis Ababa, Ethiopia, from April-
May,2018. The four federal hospitals are Amanuel 
Mental Specialized Hospital, St. Paul’s Millennium 
Medical College, St. Peter TB Specialized Hospital, 
and Alert Hospital. All hospitals are under the 
administration of the federal government of Ethiopia. 
 
Sample size and sampling techniques: The 
respondents were all HIV-positive patients attending 
the ART clinics of the four federal hospitals during the 
study period. The sample size was determined using 
the formula for a single population proportion by 
taking the prevalence of HAND (36.4%) from a study 
done in Debre Birhan Hospital, with 95% confidence 
level and 4% degree of precision. Then, by adding 10% 
of non-response rate, the final sample size totaled 584. 
A systematic random sampling technique was 
employed. The sampling interval was determined by 
dividing the total study population who had to follow-
up during one-month data collection by the total 
sample size. Proportional allocation of the sample was 































































Figure 1: Schematic presentation of proportional allocation of samples of HIV positive patients at four 
federal hospitals in Addis Ababa, Ethiopia: 2018 (n=581)
 
Data collection tools and quality controls: Data 
were collected using a standardized structured 
questionnaire. The questionnaire was first prepared in 
English, then translated into Amharic, and finally back-
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Data quality control issues were ensured by conducting 
a pre-test on 5% of the study participants. Training was 
given to data collectors and supervisors on the 
questionnaire, and on how to screen for HAND using 
IHDS. They were also informed of the purpose of the 
study and how to approach respondents and obtain 
consent. All of the data collectors working in the ART 
clinics held educational diplomas and had experience 
of data collection. Filled-in questionnaires were 
checked daily for their completeness and consistency 
by the principal investigator and supervisor. 
 
The IHDS consists of three sub tests: timed finger 
tapping, timed alternating hand sequence test and recall 
of four items. For words not recalled, the subject had 
been prompted with a ‘semantic' clue as follows: 
animal (dog, a piece of clothing (hat), vegetable (bean), 
and color (red). A half-point was assigned for each 
correct word recalled after prompting. A total score out 
of 12 was calculated for each participant, with each of 
the three subtests contributing 4 points to the total 
score.  
 
HIV associated neuro-cognitive disorder (HAND) was 
measured by the sum of a 3 item IHDS score. Any  
patient  who  score  less  than  or  equal  to  9 has 
HANDs. The tool is internal consistent to measure 
what we want to study with a cronbachs`s alpha of 
0.76. 
 
Depression was assessed using the PHQ-9 scale. PHQ-
9 is a nine-item self-report instrument. Scoring ranges 
from 0 to 27, and a score ≥5 indicates having 
depression. Medication adherence was assessed using 
an eight-item Morisky Medication Adherence Scale, 
according to which low adherence is a score <6, medium 
adherence is a score of 6 or 7, and high adherence is a 
score of 8. Perceived HIV stigma by the sum of 
perceived HIV stigma scale of 11-item score greater 
than or equal to mean, social support by the sum of 
Oslo 3-item, current substance use who use any 
substance for the last 3 months, ever substance use 
who ever uses any substance in their lifetime. Co-
morbidities were explained by the presence of 




The collected data were coded, checked for 
completeness, edited, cleaned and entered into Epi-data 
3.1 and exported to SPSS version 20.0 for analysis. 
Frequencies, proportions and cross-tabulations were 
used to summarize descriptive statistics.  
 
All variables which were significant at bivariate 
analysis were entered into multiple logistic regression 
to control for confounding factors. Finally, the 
variables which had a significant association were 
identified on the basis of AOR, with 95% CI and a p-
value less than 0.05 to fit the final regression model. 
 
Results  
Socio-demographic characteristics: Five hundred 
and eighty-one respondents were included in the study, 
making a response rate of 99.49%. Of those, the 
majority 356 (61.3%) were females and 260 (44.8%) 
were married. The mean age of the respondents was 
37.99 years (±9.83 standard deviation). Of the study 
participants, 418 (71.9%) were living with families, 
261 (44.9%) were Amhara by ethnicity, 362 (62.3%) 
were Orthodox Christians, 242 (41.7%) had a primary-
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Table 1: Socio-demographic characteristics of HIV positive patients at ART clinics of the four 
federal hospitals of Addis Ababa, Ethiopia: 2018(N= 581). 
Variables Categories Frequency  % 
Sex Male 225 38.7 
Female  356 61.3 
Age 18-25 70 12 
26-35 142 24.4 
36-45 143 24.6 
46-55 62 10.7 
≥56 164 28.2 
Marital status Single 169 29.1 
Married 260 44.8 
Divorced 103 17.7 
Other 49   8.4 
Level of education Illiterate 127 21.9 
Primary 242 41.7 
Secondary 143 24.6 
College and above 69 11.9 
Religion Orthodox 362 62.3 
Muslim 124 21.3 
Protestant     81 13.9 
Others 14 2.4 
Income < 500  158 27.2 
501-1,000  150  25.8 
1,001-2,008 128 22.0 
>2,009 145 25.0  
Occupation Governmental 185 31.8 
NGO 135  23.2 
Merchant   101  17.4 
Private 108  18.6 
Jobless 52 9.0 
Ethnicity Amhara 261 44.9 
Oromo 171 29.4 
Tigrayan 66 11.4 
Others 83 14.3 
Who do you live with Alone 137 23.6 
With families 418 71.9 
With social 26 4.5 
 
Prevalence of neuro-cognitive disorders 




Figure 2: Prevalence of HAND among HIV-positive patients at four federal hospitals in Addis 
Ababa, Ethiopia: 2018 (n=581) 
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In terms of the IHDS, 103 participants (17.7%) scored 
4 out of 4 in the timed finger tapping sub-test to assess 
motor skills; 132 (22.7%) scored 4 out of 4 to assess 
psychomotor speed; and 142 (24.4%) scored 4 out of 4 
to assess memory recall. 
 
Factors associated with neuro-cognitive disorders: 
The clinical data reviewed during the time of study 
shows that 467(80.4%) patients had poor adherence of 
ART drugs, and 253 (43.5%) had taken less than 5 
years duration on ART. In this study, 287 (49.4%) of 
the respondents had a CD4count of 500cells/µl or less 
and majority of participants were in stage I HIV 
302(52.0%)  
 
Our study shows 355(61.1%) has moderate social 
support and 308(53.0%) high perceived stigma. In this 
study, 120 (20.7%) of the respondents had current 
alcohol use followed by 112(19.3%) lifetime tobacco 
use (Table2).  
 
Table 2: Distribution of people living with HIV by their factors at four federal hospitals in Addis 
Ababa, Ethiopia: 2018 (n=581) 
Variables Categories Frequency  % 
Depression No depression 437 75.2 
Has depression 144 24.8 
Social support Poor social support 178 30.6 
Moderate social support 355 61.1 
Good social support 47 8.1 
Perceived stigma No stigma 273 47.0 
Has stigma 308 53.0 
Current Substance use                             
Alcohol use No 461 79.3 
Yes 120 20.7 
Khat use No 539 92.8 
Yes 42 7.2 
Tobacco use No 524 90.2 
Yes 57 9.8 
Others  No 569 97.9 
Yes 12 2.1 
Life time substance use    
Tobacco use No 469 80.7 
Yes 112 19.3 
Alcohol use No 385 66.3 
Yes 196 33.7 
Khat use No 501 86.2 
Yes 80 13.8 
Other No 566 97.4 
Yes 15 2.6 
Adherence Poor adherence 467 80.4 
Good adherence 114 19.6 
Duration on ART <5 253 43.5 
5-10 242 41.7 
>10 86 14.8 
≤ 500 287 49.4 
> 500 294 50.6 
HIV stage Stage 1 302 52.0 
Stage 2 236 40.6 
Stage 3 35 6.0 
Stage 4 8 1.4 
Co-morbidity Yes 115 19.8 
No 466 80.2 
 
Based on bivariate analysis, the socio-demographic 
variables of sex, educational status and income, and 
clinical variables such as WHO HIV stage, current 
tobacco use, lifetime tobacco use, perceived stigma, 
and CD4 count, were significantly associated with 
HAND. These variables were fitted into a multivariate 
binary logistic regression model in order to control for 
the effect of confounders. In the multivariate regression 
analysis a p-value <0.05 was considered a significant 
association. 
The results of multivariate binary logistic regression 
show that being illiterate and having a primary 
educational status, lifetime tobacco use, and a CD4 
count ≤500 cells/µl were factors associated with 
HAND.  
 
Respondents who were illiterate were 5.2 times more 
likely to have HAND compared to those with an 
educational status of diploma and above (AOR=5.16; 
95% CI: 2.20-12.07), and those with a primary 
27     Ethiop. J. Health Dev 
 
Ethiop. J. Health Dev.2020; 34(1) 
education were 3.3 times more likely to have HAND 
compared to those with a diploma and above 
(AOR=3.27; 95% CI: 1.46-7.29). 
 
In participants with a CD4 count less than 500 cells/µl, 
the odds of developing HAND were 1.6 times greater 
than those with a CD4 count ≥500cells/µl (AOR=1.61; 
95% CI: 1.11-2.39) (Table 3). 
 
Table 3: Bivariate and multivariate logistic regression analysis showing the associations between factors 
and HAND among HIV-positive clients at four federal hospitals in Addis Ababa, Ethiopia: 2018 (n=581) 
Variables   Categories HAND COR (95% CI) AOR (95% CI) 
Yes No 
Sex Male 68 157 1 1 
Female 139 217 1.48 (1.03 - 2.11) 1.22 (0.82 - 1.80) 
Educational status Illiterate 65 62 6.98 (3.19 - 15.28) 5.16 (2.20 - 12.07)** 
Primary 96 146 4.30 (2.08 - 9.25) 3.27 (1.46 - 7.29)* 
Secondary 37 106 2.32 (1.05 - 5.15) 1.81 (0.78 - 4.22) 
Diploma and above 9 60 1 1 
Income( Birr) ≤500 90 68 4.87 (2.93 - 8.08) 3.28 (0.88 - 5.69) 
501-1,000 45 105 1.58 (0.93 - 2.67) 1.13 (0.64 - 2.01) 
1,001-2,008 41 87 1.73 (1.01 - 2.99) 1.57 (0.87 - 2.80) 
≥ 2,009 31 114 1 1 
HIV stage Stage 1 91 211 1 1 
Stage 2 99 137 1.67 (1.17 - 2.39) 1.19 (0.78 - 1.82) 
Stages 3 and 4 17 26 1.51 (0.78 - 2.93) 1.08 (0.51 - 2.30) 
CD4 count (cells/µl) ≤500 cells/µl 116 203 1.51 (1.08 - 2.13) 1.61 (1.11 - 2.39)* 
>500 cells/µl 91 171 1 1 
Perceived stigma Yes 123 185 1.49 (1.06 - 2.10) 1.22 (0.83 - 1.79) 
No 84 189 1 1 
Lifetime tobacco use Yes 25 87 0.45 (0.28 - 0.73) 2.40 (1.44 - 4.01)* 
No 182 287 1 1 
Current  tobacco  use Yes  13 44 0.50 (0.26 - 0.95) 0.79 (0.33 - 1.94) 
No 194 330 1 1 
 
Notes: *p-value<0.05; **p-value=0.000; 1.00 = Reference; Hosmer and Lemeshow goodness-of-fit = 0.73 
 
Discussion 
HIV associated neuro-cognitive disorder in HIV/AIDS 
patients is one of the most common neurological 
condition especially in resource-limited continents like 
Africa. It ranges from as low as 10- 24% up to as much 
as 85%. HAND even in its mild form is associated with 
decrease medication adherence, and daily activity 
performance, poor quality of life and unemployment. 
 
The prevalence found in this study was in line with 
study done in Botswana (38%), Uganda (31%), and 
Ethiopia (36.4%, 33.3% and 35.7) (24-26).   
In most cases, the common factors associated were low 
level of education, lower CD4 count. 
However, the risk of HAND in our study was higher 
than a study done in North West Ethiopia (24.8%), 
South Africa (25%), Central Africa Republic (25%), 
Cameroon (22.2), Northern Nigeria (21.5%), Malawi 
(15%) and Brazil (22.6%) (9, 14, 15, 26-29). The 
differences might be accounted to the neuro virulence 
strain differences. 
 
On the other hand, this study was lower than study 
done in Switzerland (83%) (10). This difference in the 
prevalence rate might be accounted to the neuro 
virulence differences, differences in the method, and 
cut-off points of measuring instruments. 
 
Our study revealed that being illiterate and primary 
level of education was 5.16 and  3.27 times higher risk 
of developing HAND as compared to those who had a 
diploma and above educational backgrounds 
[AOR=5.16 95%CI: 2.20 - 12.07], [AOR=3.27 95%CI: 
1.46 - 7.29]  respectively. This finding was in line with 
the study done in South Asia, Northern Nigeria, 
Central African Republic and Ethiopia (9, 14, 26, 30). 
This could be due to an individual with high level of 
education level have better awareness health issues and 
their consequences than those who had low level of 
education. 
 
Study participants with CD4 count  ≤ 500 cell/µl were 
about 1.6 times more likely affected by HANDs than 
those cd4 count >500 cell/µl, [AOR=1.61 95%CI:1.11-
2.39]. This finding was also in line with study done in 
Uganda (15), Central African Republic (14), Yaoundé 
Cameroon (15), Northern Nigeria (9), Ethiopia (26),  
and Brazil (29).  This could be due to the fact that 
decrease CD4 count can expose to increasing 
susceptibility to brain infection and neuro cognitive 
impairments. 
 
Regarding the relationship between life time tobacco 
use of respondent and HANDs, those who use tobacco 
in their lifetime has 2.4 times risk for HANDs as 
compared to those who never use tobacco in their 
lifetime [AOR: 2.40 95%CI: 1.44-4.01].This could be 
due to the effect of tobacco on brain cells which kills 
and stops forming of new brain cells. This finding was 
in line with study done on USA, and against the study 
done on Botswana (24, 31).  
 
Conclusion 
Our study revealed, high prevalence of HAND in HIV 
positive patients in Addis Ababa, Ethiopia.  
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Being illiterate, lower level of education, CD4 count ≤ 
500cell/µl, and life time tobacco use were significantly 
associated with HAND among HIV/AIDS patients. 
Screening for HAND is crucial, in all clinical service 
for HIV/AIDS patients giving special attention for 
these having lower level of education, low cd4 count, 
and tobacco users.  
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